[Federal Register Volume 61, Number 138 (Wednesday, July 17, 1996)]
[Notices]
[Page 37280]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-18102]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES

Prospective Grant of Exclusive License: Method of Treating 
Demyelinating Diseases With Insulin-Like Growth Factor I

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license in the United States to practice the invention 
embodied in U.S. Patent Application Serial Number 60/003,055, filed on 
August 31, 1995, entitled ``Method of Treating Demyelinating Diseases 
With Insulin-Like Growth Factor I'', to Cephalon, Inc., having a place 
of business in West Chester, Pennsylvania. The patent rights in this 
invention have been assigned to the United States of America.
    The patent application claims a method to treat diseases or 
disorders associated with myelin injury, such as multiple sclerosis, by 
administering an effective amount of insulin-like growth factor I.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless, within 90 days 
from the date of this published Notice, NIH receives written evidence 
and argument that establishes that the grant of the license would not 
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    The field of use would be the use of insulin-like growth factor I 
to treat nervous system disorders associated with perivascular lesions, 
such as those occurring in multiple sclerosis.

ADDRESSES: Requests for a copy of the patent applications, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Leopold J. Luberecki, Jr., J.D., Technology 
Licensing Specialist, Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Box 13, Rockville, MD 
20852-3804. Telephone: (301) 496-7735, ext. 223; Facsimile: (301) 402-
0200. Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Only written comments and/or application for a 
license which are received by the NIH Office of Technology Transfer on 
or before October 15, 1996 will be considered.
    Comments and objections submitted in response to this notice will 
not be made available for public inspection, and, to the extent 
permitted by law, will not be released under the Freedom of Information 
Act, 5 U.S.C. 552.

    Dated: July 8, 1996.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 96-18102 Filed 7-16-96; 8:45 am]
BILLING CODE 4140-01-M